[5] Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. [6] Howell E, Baumgartner HM, Zallar LJ, et al. Glucagon-LikePeptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT(2c)) Receptor Agonists in the Ventral Tegm...
文献索引: [1]Ussher, J.R., Drucker, D.J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20, 463–474 (2023). [2]Mitchel L. Zoler. Semaglutide Cuts Cardiovascular Events in Landmark Trial. Medscape. August 08, 2023. 跳转链接...
可以预期,随着研究的进一步开展,GLP-1在未来T2DM的治疗中将发挥更大作用,依从性和治疗效果更好的GLP-1产品将改善糖尿病患者的治疗现状。 参考文献: 1. Drucker DJ., et al. Mechanisms of Action and TherapeuticApplication of Glucagon-like Peptide-1. Cell Metabolism. 2018; 27: 740-756. ...
[34] Drucker, D.J. 2018. Mechanisms of Action and Therapeutic Application of Glucagonlike Peptide-1. Cell Metab 27:740-756. [35] Fridolf, T., Bottcher, G., Sundler, F., Ahren, B. 1991. GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretio...
[33] Doyle ME, Egan J M,2007. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113:546-593. [34] Cheng X, Ji Z, Tsalkova T, Mei F,2008. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (Shanghai) 40:651-662. ...
[5] Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. [6] Howell E, Baumgartner HM, Zallar LJ, et al. Glucagon-LikePeptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT(2c)) Receptor Agonists in the Ventral Tegm...
[34] Drucker, D.J. 2018. Mechanisms of Action and Therapeutic Application of Glucagonlike Peptide-1. Cell Metab 27:740-756. [35] Fridolf, T., Bottcher, G., Sundler, F., Ahren, B. 1991. GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretio...
[1]Ussher, J.R., Drucker, D.J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20, 463–474 (2023). [2]Mitchel L. Zoler. Semaglutide Cuts Cardiovascular Events in Landmark Trial. Medscape. August 08, 2023. 跳转链接:[2]Regina...
[34] Drucker, D.J. 2018. Mechanisms of Action and Therapeutic Application of Glucagonlike Peptide-1. Cell Metab 27:740-756. [35] Fridolf, T., Bottcher, G., Sundler, F., Ahren, B. 1991. GLP-1 and GLP-1(7-36) amide:...
[33] Doyle ME, Egan J M,2007. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113:546-593. [34] Cheng X, Ji Z, Tsalkova T, Mei F,2008. Epac and PKA: a tale of two intracellular cAMP rece...